TFF Pharmaceuticals

TFF Pharmaceuticals, Inc. engages in the development and commercialization of drug products based on its patented Thin Film Freezing technology platform. It focuses on the manufacture of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company was founded on January 24, 2018 and is headquartered in Fort Worth, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Two Presentations Featuring Thin Film Freezing Technology Selected for the Meeting's Special Poster Collections

TFF Pharmaceuticals Announces Presentation of Data Featuring Applications of Thin Film Freezing Technology at AAPS PharmSci 360 Meeting

FORT WORTH, Texas, Sept. 26, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that President and CEO Glenn Mattes will be participating in the Roth Inaugural Healthcare Opportunities Conference being held in-person at The Yale Club in New York City on October 6, 2022. Company management will also be participating in one-on-one meetings throughout the conference.

TFF Pharmaceuticals to Participate in the Roth Inaugural Healthcare Opportunities Conference

Two Abstracts Selected for Presentation as part of the Meeting's Special Poster Collections

TFF Pharmaceuticals Announces Acceptance of Multiple Abstracts Featuring Applications of Thin Film Freezing Technology at the Upcoming AAPS PharmSci 360 Meeting

Dr. Bradley Gardiner from the Royal Alfred Hospital in Melbourne, Australia presented results from compassionate use of treating pulmonary fungal infections in a lung transplant patient

TFF Pharmaceuticals Announces Presentation of Patient Data with Voriconazole Inhalation Powder (TFF VORI) at the 15th International Congress on Lung Transplantation

FORT WORTH, Texas, Sept. 06, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that President and CEO Glenn Mattes will be participating in the H.C. Wainwright 24th Annual Global Investment Conference being held September 12 – 14, 2022 at the Lotte New York Palace in New York City. Company management will also be participating in one-on-one meetings throughout the conference.

TFF Pharmaceuticals to Participate at The H.C. Wainwright 24th Annual Global Investment Conference

While the company added three more big pharma partners, this is not what shareholders prefer to hear as the company already has more than two dozen of these. These partnerships are mostly in the pre-clinical phase and are unlikely to lead to near-time monetization.

TFF Pharma: The Potential Is Still Very Much Present

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Corey Davis - LifeSci Advisors Glenn Mattes - President, CEO & Director Kirk Coleman - Chief Financial Officer Dale Christensen - Director of Clinical Development Chris Cano - Chief Operating Officer. Bill Williams - University of Texas at Austin Conference Call Participants Jonathan Aschoff - ROTH Capital Partners Daniel Carlson - TW Research Group Michael Okunewitch - Maxim Group Operator Thank you for standing by.

TFF Pharmaceuticals, Inc. (TFFP) CEO Glenn Mattes on Q2 2022 Results - Earnings Call Transcript

Phase 2 Inhaled Voriconazole Powder and Inhaled Tacrolimus Powder Programs Continue to Advance

TFF Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Once promising, TFF Pharma is now cash-strapped and stagnant. TFFP badly needs some good news.

TFF Pharmaceuticals: Q3 Data Is Pivotal In So Many Ways

Company conference call and webcast at 4:30 PM ET Company conference call and webcast at 4:30 PM ET

TFF Pharmaceuticals to Hold Second Quarter 2022 Financial and Business Results Conference Call on August 11, 2022

New Facility in Austin Will Enable Increased Capacity for Internal Pipeline Assets While Accommodating Growing Interest in Partnered Projects

TFF Pharmaceuticals Expands R&D Operations with New Austin Facility

FORT WORTH, Texas, June 09, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that President and CEO Glenn Mattes will be participating in the JMP Securities Life Sciences Conference being held June 15 – 16, 2022 at the Lotte New York Palace in New York City. Company management will also be participating in one-on-one meetings throughout the conference.

TFF Pharmaceuticals to Participate at The JMP Securities Life Sciences Conference

FORT WORTH, Texas, June 01, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that President and CEO Glenn Mattes will be participating in the Jefferies Healthcare Conference being held June 8 – 10, 2022 in New York City. Company management will also be participating in one-on-one meetings throughout the conference.

TFF Pharmaceuticals to Participate at the Jefferies Healthcare Conference

The mean of analysts' price targets for TFF Pharmaceuticals, Inc. (TFFP) points to a 233.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think TFF Pharmaceuticals, Inc. (TFFP) Could Surge 233%: Read This Before Placing a Bet

TFFP is a platform company with leading technology. Clinical/FDA risk is extremely low.

TFF Pharmaceuticals: A Highly Attractive Basket Of Options

FORT WORTH, Texas, May 20, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that President and CEO Glenn Mattes will be virtually participating in the H.C. Wainwright Global Investment Conference being held May 23 - 26, 2022. Company management will also be participating in virtual one-on-one meetings throughout the conference.

TFF Pharmaceuticals to Participate at the H.C. Wainwright Global Investment Conference

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Corey Davis - LifeSci Advisors Glenn Mattes - President, CEO & Director Kirk Coleman - CFO, Treasurer & Secretary Christopher Cano - COO & VP, Business Development Bill Williams - University of Texas, Austin Dale Christensen - Head, Clinical Development Conference Call Participants Jonathan Aschoff - ROTH Capital Partners Daniel Carlson - TW Research Yuan Zhi - B. Riley Securities Richard Deutsch - National Securities.

TFF Pharmaceuticals, Inc. (TFFP) CEO Glenn Mattes on Q1 2022 Results - Earnings Call Transcript

TFF Pharmaceuticals, Inc. (TFFP) delivered earnings and revenue surprises of 13.16% and 33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

TFF Pharmaceuticals, Inc. (TFFP) Reports Q1 Loss, Misses Revenue Estimates

Announced Collaboration with Catalent to Further Expand Thin Film Freezing Applications with a Focus on Biologic Drug Development

TFF Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

Thin Film Freezing Technology Co-Inventor Dr. Robert O. Williams III to Deliver Platform Presentation of Data on Stabilizing and Delivering Antivirals, Antibodies and Vaccines using Thin Film Freezing Technology in the Fight Against COVID-19

TFF Pharmaceuticals Announces Multiple Presentations Highlighting Broad Applicability of its Thin Film Freezing Technology at Respiratory Drug Delivery Meeting (RDD)

TFF Pharmaceuticals to Hold First Quarter 2022 Financial and Business Results Conference Call on May 11, 2022

Niclosamide Inhalation Powder Well Tolerated with No Serious Adverse Events Across All Subject Cohorts

TFF Pharmaceuticals Announces Safety and Pharmacokinetic Data from Phase 1 Study of Niclosamide Inhalation Powder

TFF Pharmaceuticals, Inc. (TFFP) CEO Glenn Mattes on Q4 2021 Results - Earnings Call Transcript

TFF Pharmaceuticals, Inc. (TFFP) delivered earnings and revenue surprises of -33.33% and 98.72%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

TFF Pharmaceuticals, Inc. (TFFP) Reports Q4 Loss, Lags Revenue Estimates

Pipeline Advancement Continues with Ongoing Phase 2 Studies for Voriconazole and Tacrolimus Programs

News for TFF Pharmaceuticals Stock (TFFP)